参考文献/References:
[1]Le MH,Yeo YH,Li X,et al.2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis[J].Clin Gastroenterol Hepatol,2022,20(12):2809-2817.e28.[2]Simon TG,Roelstraete B,Khalili H,et al.Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort[J].Gut,2021,70(7):1375-1382.[3]Eslam M,Valenti L,Romeo S.Genetics and epigenetics of NAFLD and NASH: Clinical impact[J].J Hepatol,2018,68(2):268-279.[4]Santos-Laso A,Gutiérrez-Larra?觡aga M,Alonso-Pe?觡a M,et al.Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets[J].Biomedicines,2021,10(1):46.[5]Ahadi M,Molooghi K,Masoudifar N,et al.A review of non-alcoholic fatty liver disease in non-obese and lean individuals[J].J Gastroenterol Hepatol,2021,36(6):1497-1507.[6]Yuan F,Gu Z,Bi Y,et al.The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population[J].Aging (Albany NY),2022,14(6):2736-2747.[7]Trépo E,Valenti L.Update on NAFLD genetics: From new variants to the clinic[J].J Hepatol,2020,72(6):1196-1209.[8]Salari N,Darvishi N,Mansouri K,et al.Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis[J].BMC Endocr Disord,2021,21(1):125.[9]Pusec CM,De Jesus A,Khan MW,et al.Hepatic HKDC1 Expression Contributes to Liver Metabolism[J].Endocrinology,2019,160(2):313-330.[10]Negoita F,Blomdahl J,Wasserstrom S,et al.PNPLA3 variant M148 causes resistance to starvation-mediated lipid droplet autophagy in human hepatocytes[J].J Cell Biochem,2019,120(1):343-356.[11]BasuRay S,Wang Y,Smagris E,et al.Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis[J].Proc Natl Acad Sci U S A,2019,116(19):9521-9526.[12]陈立震.TM6SF2基因E167K多态性联合PNPLA3基因I148M多态性在非酒精性脂肪肝发生中的作用研究[D].青岛:中国海洋大学,2019.[13]BasuRay S,Smagris E,Cohen JC,et al.The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation[J].Hepatology,2017,66(4):1111-1124.[14]Mitsche MA,Hobbs HH,Cohen JC.Patatin-like phospholipase domain–containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets[J].J Biol Chem,2018,293(18):6958-6968.[15]Donati B,Motta BM,Pingitore P,et al.The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage[J].Hepatology,2016,63(3):787-798.[16]Luukkonen PK,Nick A,H?觟ltt?覿-Vuori M,et al.Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids[J].JCI Insight,2019,4(16):e127902.[17]Kozlitina J,Smagris E,Stender S,et al.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease[J].Nat Genet,2014,46(4):352-356.[18]Newberry EP,Hall Z,Xie Y,et al.Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer[J].Hepatology,2021,74(3):1203-1219.[19]Liu YL,Reeves HL,Burt AD,et al.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease[J].Nat Commun,2014,5:4309.[20]Luukkonen PK,Zhou Y,Nidhina Haridas PA,et al.Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD[J].J Hepatol,2017,67(1):128-136.[21]Kim DS,Jackson AU,Li YK,et al.Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns[J].J Lipid Res,2017,58(7):1471-1481.[22]Darabi M,Kontush A.High-density lipoproteins (HDL): Novel function and therapeutic applications. Biochim Biophys Acta Mol Cell Biol Lipids[J].2022,1867(1):159058.[23]Ramms B,Gordts PLSM.Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism[J].Curr Opin Lipidol,2018,29(3):171-179.[24]Chen BF,Chien Y,Tsai PH,et al.A PRISMA-compliant meta-analysis of apolipoprotein C3 polymorphisms and nonalcoholic fatty liver disease[J].J Chin Med Assoc,2021,84(10):923-929.[25]Jain V,Kumar A,Ahmad N,et al.Genetic polymorphisms associated with obesity and non-alcoholic fatty liver disease in Asian Indian adolescents[J].J Pediatr Endocrinol Metab,2019,32(7):749-758.[26]Kumar A,Shalimar,Walia GK,et al.Genetics of nonalcoholic fatty liver disease in Asian populations[J].J Genet,2019,98:29.[27]Xu QY,Li H,Cao HX,et al.APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease[J].Biomed Res Int,2020,2020:8869674.[28]Morze J,Koch M,Aroner SA,et al.Associations of HDL Subspecies Defined by ApoC3 with Non-Alcoholic Fatty Liver Disease: The Multi-Ethnic Study of Atherosclerosis[J].J Clin Med,2020,9(11):3522.[29]Thangapandi VR,Knittelfelder O,Brosch M,et al.Loss of hepatic Mboat7 leads to liver fibrosis[J].Gut,2021,70(5):940-950.[30]Zusi C,Morandi A,Maguolo A,et al.Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children[J].Nutr Metab Cardiovasc Dis,2021,31(5):1548-1555.[31]Helsley RN,Varadharajan V,Brown AL,et al.Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease[J].Elife,2019,8:e49882. [32]Mancina RM,Dongiovanni P,Petta S,et al.The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent[J].Gastroenterology,2016,150(5):1219-1230.e6.[33]Caddeo A,Jamialahmadi O,Solinas G,et al.MBOAT7 is anchored to endomembranes by six transmembrane domains[J].J Struct Biol,2019,206(3):349-360.[34]Tanaka Y,Shimanaka Y,Caddeo A,et al.LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover[J].Gut,2021,70(1):180-193.[35]Pi?觡eiro R,Maffucci T,Falasca M.The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation[J].Oncogene,2011,30(2):142-152.[36]Zain SM,Mohamed Z,Mohamed R.Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis[J].J Gastroenterol Hepatol,2015,30(1):21-27.[37]Mohammadi S,Farajnia S,Shadmand M,et al.Association of rs780094 polymorphism of glucokinase regulatory protein with non-alcoholic fatty liver disease[J].BMC Res Notes,2020,13(1):26.[38]Li J,Zhao Y,Zhang H,et al.Contribution of Rs780094 and Rs1260326 Polymorphisms in GCKR Gene to Non-alcoholic Fatty Liver Disease: A Meta-Analysis Involving 26,552 Participants[J].Endocr Metab Immune Disord Drug Targets,2021,21(9):1696-1708.[39]Sliz E,Sebert S,Würtz P,et al.NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects[J].Hum Mol Genet,2018,27(12):2214-2223.[40]Ghodsian N,Abner E,Emdin CA,et al.Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease[J].Cell Rep Med,2021,2(11):100437.[41]Samuel VT,Shulman GI.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases[J].Cell Metab,2018,27(1):22-41.[42]Gao H,Liu S,Zhao Z,et al.Association of GCKR Gene Polymorphisms with the Risk of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease in a Chinese Northern Han Population[J].J Clin Transl Hepatol,2019,7(4):297-303.[43]Lin Z,Wang Y,Zhang B,et al.Association of type 2 diabetes susceptible genes GCKR, SLC30A8, and FTO polymorphisms with gestational diabetes mellitus risk: a meta-analysis[J].Endocrine,2018,62(1):34-45.
相似文献/References:
[1]谢雨萌,毛乾国.非酒精性脂肪肝患者中医体质及相关证型研究[J].医学信息,2018,31(07):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
XIE Yu-meng,MAO Qian-guo.Study on TCM Constitution and Correlative Syndromes of Nonalcoholic Fatty Liver Patients[J].Journal of Medical Information,2018,31(24):46.[doi:10.3969/j.issn.1006-1959.2018.07.016]
[2]刘 瑜,王 星,代 萌,等.2型糖尿病合并非酒精性脂肪肝的危险因素研究[J].医学信息,2018,31(23):108.[doi:10.3969/j.issn.1006-1959.2018.23.029]
LIU Yu,WANG Xing,DAI Meng,et al.Study on Risk Factors of Type 2 Diabetes Mellitus with Non-alcoholic Fatty liver Disease[J].Journal of Medical Information,2018,31(24):108.[doi:10.3969/j.issn.1006-1959.2018.23.029]
[3]于 淙,欧阳天佐,周 培.吡格列酮治疗非酒精性脂肪肝有效性及安全性的Meta分析[J].医学信息,2020,33(13):60.[doi:10.3969/j.issn.1006-1959.2020.13.017]
YU Cong,OUYANG Tian-zuo,ZHOU Pei.Meta-analysis of the Efficacy and Safety of Pioglitazone in the Treatment of Non-alcoholic Fatty Liver[J].Journal of Medical Information,2020,33(24):60.[doi:10.3969/j.issn.1006-1959.2020.13.017]
[4]秦 莉,邱秀霞.肝病降脂颗粒对非酒精性脂肪肝患者肝脏生化及血脂水平的影响[J].医学信息,2022,35(21):65.[doi:10.3969/j.issn.1006-1959.2022.21.014]
QIN Li,QIU Xiu-xia.Effect of Ganbing Jiangzhi Granules on Liver Biochemistry and Blood Lipid Levels in Patients with Nonalcoholic Fatty Liver Disease[J].Journal of Medical Information,2022,35(24):65.[doi:10.3969/j.issn.1006-1959.2022.21.014]
[5]黄丽玲,吴春城,梁惠卿,等.血清标志物壳多糖酶3样蛋白1评价肝纤维化的研究[J].医学信息,2021,34(10):32.[doi:10.3969/j.issn.1006-1959.2021.10.009]
HUANG Li-ling,WU Chun-cheng,LIANG Hui-qing,et al.Serum Marker Chitinase 3-like Protein 1 in the Evaluation of Liver Fibrosis[J].Journal of Medical Information,2021,34(24):32.[doi:10.3969/j.issn.1006-1959.2021.10.009]
[6]郭月欢,甘惠中.幽门螺旋杆菌感染与非酒精性脂肪肝的相关性研究[J].医学信息,2022,35(08):89.[doi:10.3969/j.issn.1006-1959.2022.08.021]
GUO Yue-huan,GAN Hui-zhong.Correlation Between Helicobacter Pylori Infection and Nonalcoholic Fatty Liver Disease[J].Journal of Medical Information,2022,35(24):89.[doi:10.3969/j.issn.1006-1959.2022.08.021]
[7]陈 超,陈冯梅.血清尿酸/肌酐比值与老年人非酒精性脂肪肝的相关性研究[J].医学信息,2023,36(19):71.[doi:10.3969/j.issn.1006-1959.2023.19.014]
CHEN Chao,CHEN Feng-mei.Correlation Between Serum Uric Acid/Creatinine Ratio and Nonalcoholic Fatty Liver Disease in the Elderly[J].Journal of Medical Information,2023,36(24):71.[doi:10.3969/j.issn.1006-1959.2023.19.014]